These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27919088)

  • 1. Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents.
    Zhang XL; Xu B
    Ann Intern Med; 2016 Dec; 165(11):829. PubMed ID: 27919088
    [No Abstract]   [Full Text] [Related]  

  • 2. Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents.
    Shah R
    Ann Intern Med; 2016 Dec; 165(11):828-829. PubMed ID: 27919089
    [No Abstract]   [Full Text] [Related]  

  • 3. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Kandzari DE; Mauri L; Koolen JJ; Massaro JM; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    Lancet; 2017 Oct; 390(10105):1843-1852. PubMed ID: 28851504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
    Arroyo D; Gendre G; Schukraft S; Kallinikou Z; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Togni M; Cook S; Puricel S
    Int J Cardiol; 2017 Sep; 243():121-125. PubMed ID: 28576627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioresorbable polymer drug-eluting stents.
    Shah R
    Lancet; 2018 Mar; 391(10124):935-936. PubMed ID: 29536854
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioresorbable polymer drug-eluting stents.
    Alkhalil M
    Lancet; 2018 Mar; 391(10124):936. PubMed ID: 29536856
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial.
    Kerkmeijer LSM; Tijssen RYG; Hofma SH; van der Schaaf RJ; Arkenbout KE; Kraak RP; Weevers A; Piek JJ; de Winter RJ; Tijssen JGP; Henriques JPS; Wykrzykowska JJ;
    EuroIntervention; 2019 Sep; 15(7):603-606. PubMed ID: 31147304
    [No Abstract]   [Full Text] [Related]  

  • 11. Coronary bifurcations: still the touchstone of drug-eluting stents and bioresorbable vascular scaffolds?
    von Birgelen C; van Houwelingen KG; Lam MK
    Rev Esp Cardiol (Engl Ed); 2014 Oct; 67(10):787-9. PubMed ID: 25262123
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioresorbable polymer drug-eluting stents - Authors' reply.
    Kandzari DE; Mauri L; Koolen JJ; Doros G; Waksman R
    Lancet; 2018 Mar; 391(10124):936-937. PubMed ID: 29536855
    [No Abstract]   [Full Text] [Related]  

  • 13. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
    de Winter RJ; Katagiri Y; Asano T; Milewski KP; Lurz P; Buszman P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Ophuis TO; Wöhrle J; Wyderka R; Cayla G; Hofma SH; Levesque S; Żurakowski A; Fischer D; Kośmider M; Goube P; Arkenbout EK; Noutsias M; Ferrari MW; Onuma Y; Wijns W; Serruys PW
    Lancet; 2018 Feb; 391(10119):431-440. PubMed ID: 29203070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.
    Sotomi Y; Suwannasom P; Tenekecioglu E; Tateishi H; Abdelghani M; Serruys PW; Onuma Y
    Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1127-45. PubMed ID: 26401921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
    Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
    Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
    Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial).
    Katagiri Y; Onuma Y; Asano T; Iñiguez A; Jensen LO; Cequier À; Hofma SH; Christiansen EH; Suttorp M; Brugaletta S; Räber L; Sabaté M; Windecker S; Serruys PW
    EuroIntervention; 2018 Dec; 14(11):e1224-e1226. PubMed ID: 30398967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.